Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Insulin Pricing, PBM Relationships Under Government Microscope

Executive Summary

Minnesota Attorney General demands Novo Nordisk and Sanofi provide information on their insulin pricing; they are also among several companies facing probes over their contracts with pharmacy benefit managers.

Advertisement

Related Content

Which Pharma Firm Increases US Prices The Most?
Which Pharma Firm Increases US Prices The Most?
Janssen's Drug Pricing Report Emphasizes Value Of Rebates
Generic Industry Hit With Avalanche Of Price Fixing Suits
Diabetes Rebate Model Challenged On Morality Grounds In Class Action Suit
Lilly’s Insulin Discounts Target High-Deductible Insurance Gaps
Pharma Deals With The DOJ
Pharma Pricing, Non-Profit Ties Get Increasing Scrutiny From Prosecutors

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS120236

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel